WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Phreesia, Inc. (NYSE: PHR) between May 8, 2025 and March 30, 2026, inclusive (the “Class Period”), of the important July 13, 2026 lead plaintiff deadline.
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Babcock & Wilcox Enterprises, Inc. (“B&W”) (NYSE: BW) between November 5, 2025 and March 11, 2026, inclusive (the “Class Period”), of the important June 15, 2026 lead plaintiff deadline.
In 2026, Nalvurikenz officially announced the release of its new AI-powered trading platform, integrating unique features and functionalities to simplify the trading process using a combination of artificial intelligence, live data analytics, and advanced automation.
COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated sustained efficacy and safety in adults with hypoparathyroidism. Over the three-and-a-half-year duration of the trial, TransCon PTH replicated the systemic actions of endogenous PTH, with a balanced, beneficial impact on the main target organ systems – CNS, kidney, small intestine, and bone – as demonstrated by improved quality of life and normalized and stable urine calcium, serum calcium, serum phosphate, and bone mineral density. These benefits were sustained while enabling independence from conventional therapy with active vitamin D and calcium.
Toronto, ON, June 10, 2026 (GLOBE NEWSWIRE) -- Capstone Infrastructure Corporation (“Capstone” or the “Corporation”) (TSX:CSE.PR.A) announced today that it does not intend to exercise its right under the terms of its Cumulative 5-Year Rate Reset Preferred Shares, Series A (the “Series A shares”) to redeem all or part of the currently outstanding 3,000,000 Series A shares on July 31, 2026. As a result, subject to certain conditions, the holders of the Series A shares have the right to convert all or part of their Series A shares, on a one-for-one basis, into Cumulative Floating Rate Preferred Shares, Series B (the “Series B shares”) on July 31, 2026 (the “Conversion Date”) in accordance with the terms of the Series A shares.
THE WOODLANDS, Texas, June 10, 2026 /PRNewswire/ -- MIND Technology, Inc. (NASDAQ: MIND) ("MIND" or the "Company") today announced financial results for its fiscal...
TEL AVIV, Israel, June 10, 2026 (GLOBE NEWSWIRE) -- ZOOZ Strategy Ltd. (Nasdaq and TASE: ZOOZ) (“ZOOZ” or the “Company”) today announced that its Board of Directors has authorized management to explore a range of strategic alternatives that could potentially complement the Company’s existing bitcoin treasury strategy and enhance long-term shareholder value.
NextEra Energy Transmission's newest transmission line in New Mexico is projected to reduce residential electric bills by approximately $13 a monthHOBBS, N.M., June 10,...
FranklinWH joins San José Clean Energy's Peak Rewards for Smart Homes program, offering battery owners upfront incentives and ongoing bill credits for helping stabilize...
NORWALK, Conn., June 10, 2026 /PRNewswire/ -- GameChange Energy, a global energy infrastructure company, announced that it has been ranked the world's second-largest solar tracker...
ATHENS, Greece, June 10, 2026 (GLOBE NEWSWIRE) -- Imperial Petroleum Inc. (Nasdaq: IMPP) (the “Company”), a ship-owning company providing petroleum products, crude oil, and drybulk seaborne transportation services, today announced a dividend of $0.546875 per share on its 8.75% Series A Cumulative Redeemable Perpetual Preferred Stock (the “Series A Preferred Shares”), payable on June 30, 2026 to holders of record as of June 25, 2026. The dividend payment relates to the period from the last dividend payment date for the Series A Preferred Shares on March 30, 2026 through June 29, 2026.
The cost-effective platform delivers rapid pharmacological validation data in cynomolgus monkeys, helping biotech firms make confident R&D decisions before committing to full-scale IND studies.BOSTON...
WARWICK, NY, June 10, 2026 (GLOBE NEWSWIRE) -- Ozop Energy Solutions, Inc. (OTC: OZSC, the “Company”) today announced Ballislife Drink Inc.’s entry into the Southern California market through Varon Corp’s U.S. subsidiary, Varon USA, supported by the appointment of Tenace Consulting (Tenace) as its regional distribution partner. Ozop and Varon Corp are currently completing customary pre-closing conditions in connection with the previously announced transaction with OZOP.